During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...
The dopamine D2 receptor (D2R) is a validated target for the treatment of neuropsychiatric disorders. Many antipsychotics, however, do not just target the D2R, which explains the number of side ...
The Brighterside of News on MSN
New research challenges our understanding of Parkinson’s disease
A research team led by McGill University has taken a close look at a long-standing idea about Parkinson’s disease and found ...
New findings argue against a direct causal role for dopamine during the experience of a treatment effect in the establishment of positive treatment expectations and placebo analgesia in healthy ...
Migraines are a leading cause of disability. Worldwide about 14.7 percent of people experience migraines. Migraines entail severe pain as well as increased sensitivity to usually non-painful stimuli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback